Prevalence of antibodies in the cystic fibrosis patients
| Subjects n | 144 |
| ASCA-IgA >25 IU·mL−1 | 43.7 |
| ASCA-IgA associated with ASCA-IgG | 21.8 |
| ANCA >1/20 | 40 |
| Anti-BPI ≥1 AU·mL−1 | 23.6 |
| Anti-PR3, anti-MPO | 0 |
| ANA >1/80 | 25 |
| Anti-dsDNA antibodies ≥5 IU·mL−1 | 0.7 |
| ENA | 0 |
| IgM rheumatoid factor >1.3 AU·mL−1 | 2.7 |
| Anti-CCP antibodies >25 IU·mL−1 | 7.6 |
| Anti-CCP associated with IgM rheumatoid factor | 1.5 |
| Anti-gliadin IgA >50 IU·mL−1 | 12.5 |
| Anti-GAD >1 IU·mL−1 | 2 |
| Anti-IA-2 >0.75 IU·mL−1 | 1.5 |
| Anti-actin >1/50 | 1.5 |
| Anti-thyroperoxidase >60 IU·mL−1 | 2 |
Data are presented as %, unless otherwise stated. ASCA: anti-Saccharomyces cerevisiae antibodies; Ig: immunoglobulins; ANCA: antineutrophil cytoplasmic antibodies; BPI: bactericidal/permeability-increasing protein; PR3: proteinase-3; MPO: myeloperoxidase; ANA: antinuclear antibodies; ENA: extractable nuclear antigens; CCP: cyclic citrullinated peptide; GAD: glutamic acid decarboxylase; IA-2: Islet antigen-2.